MD Anderson Ties With Pharmaceuticals Developer Ionis

The University of Texas MD Anderson Cancer Center is in a research collaboration with biopharmaceuticals firm Ionis Pharmaceuticals, the two said this morning. Financial details of the deal were not disclosed. The two said the strategic alliance focuses on the discovery and development of novel cancer therapeutics, and will combine antisense technology from Ionis with expertise at MD Anderson, to treat a variety of cancer in patients. According to MD Anderson and Ionis, they will work together to validate novel undruggable cancer targets selected based on human genomic data, said will ultimately to identify a partner to complete development and to commercialize any drugs derived from any R&D efforts.